The discovery of somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) (1, 2) drastically changed the therapeutic perspective of non-small-cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.